The purpose of this research is to evaluate how effective UGN-104 is at removing tumors in patients with this type of cancer. The medication will be given directly into the upper urinary tract through a procedure called intravesical administration. Each patient will receive six treatments of the medicine over a treatment period that can last up to 12 months.

After completing the treatment, patients will have a check-up approximately 5 weeks after their final dose to determine if the treatment was successful in eliminating the cancer. The study will continue to monitor patients to see how long the treatment effects last and to check for any side effects. Throughout the study, doctors will perform various tests to ensure patient safety, including blood tests and imaging of the urinary tract.

The purpose of the study is to determine how well these new treatments work in extending the life of patients with this advanced cancer. Participants in the study will receive either the new treatment or the standard chemotherapy. Some participants may receive a combination of MEDI4736 and tremelimumab, while others will receive MEDI4736 alone. The study will also include a group of patients who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the progress of their cancer. The study aims to provide valuable information on whether these new treatments can offer better outcomes for patients with Stage IV Urothelial Cancer compared to the current standard of care. The trial is expected to continue until the end of 2025, with recruitment starting in September 2024.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to evaluate how safe and effective TOOKAD is in treating this type of cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the drug is given directly into a vein. The drug is then activated by a laser light delivery system, which helps to target the cancer cells more precisely. The study will monitor the participants over a period of time to see how well the treatment works and to check for any side effects.

Throughout the study, researchers will look for the absence of cancer in the treated areas, such as the kidney and ureter, using methods like endoscopy, which is a procedure that allows doctors to look inside the body. The study will also assess the overall health of the kidney and whether the treatment helps in preserving kidney function. Safety follow-ups will be conducted to record any adverse events experienced by the participants. The study aims to provide valuable information on the effectiveness and safety of TOOKAD in treating Low-Grade Upper Tract Urothelial Cancer.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor how well the treatments work in reducing the size of the cancer and how safe they are for patients. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments.

The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The goal is to gather information on how these treatments can help manage urothelial cancer and improve patient outcomes. This research is important for developing new and effective ways to treat this type of cancer.

The purpose of the study is to compare the effectiveness of the combination treatment with the standard chemotherapy in people who have not received prior treatment for their advanced or metastatic urothelial cancer. Participants will be randomly assigned to one of the two treatment groups. The study will monitor the participants over a period of time to see how well the cancer responds to the treatments and to assess overall survival rates.

Throughout the study, participants will receive regular medical check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study aims to provide valuable information on whether the combination of enfortumab vedotin and pembrolizumab offers better outcomes compared to the standard chemotherapy options for patients with this type of cancer.

Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study will look at how the cancer responds to the treatment, including whether it shrinks or stops growing. The study will also assess how long patients live without the cancer getting worse. Some participants may receive other medications as part of their treatment, such as cisplatin, gemcitabine, carboplatin, pembrolizumab (also known as Keytruda), avelumab (also known as Bavencio), domvanalimab (also known as AB154), and zimberelimab (also known as AB122).

The study is designed to gather information on the effectiveness and safety of sacituzumab govitecan in treating this type of cancer. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to collect data on the treatment’s impact on their cancer. The study aims to provide valuable insights that could lead to improved treatment options for patients with urothelial cancer.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

The purpose of the study is to see how well sacituzumab govitecan works in helping patients live longer compared to other treatments. Participants in the study will receive either sacituzumab govitecan or a treatment selected by their doctor, which could include medications like docetaxel, vinflunine, or paclitaxel. These treatments are given as solutions for infusion, meaning they are administered directly into the bloodstream through a vein.

The study will follow participants over a period of time to monitor their health and the effects of the treatments. The goal is to gather information on how these treatments impact overall survival and other health outcomes in patients with advanced urothelial cancer. This information will help doctors understand which treatments may be most effective for this type of cancer.